BmemHLA : Origins of the Heterogeneity of the Anti-HLA Memory B Cells in Kidney Transplantation
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux
About this trial
This study will describe the transcriptomic and phenotypic characteristics of anti-HLA memory B cells by comparing five groups of patients awaiting renal transplantation: patients with a single history of pregnancy, transfusion or failure of a first renal transplant requiring transplantectomy within 3 months of transplantation, or after 3 months, and patients without an immunizing allogeneic event. The hypothesis is that these five contexts induce different types of memory B cells with different modalities of reactivation and post-transplant pathogenicity.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult kidney transplantation candidate at CHU de Bordeaux
Sensitized against class I HLA
Only on type of sensitizing event among : transfusion, pregnancy, previous transplantation, no senitizing event
Disqualifiers
Pediatric kidney transplantation candidate at CHU de Bordeaux
Rituximab injection
Ongoing treatment with immunosuppressive drugs
Non-cutaneous carcinoma, chronic viral infection
Trial design
Design model
Parallel
Treatments tested in this trial
Identification of types of anti-HLA-specific memory LBs
Other interventionUsing blood sample, it will be perform single cell RNA sequencing of sorted anti-HLA B cells, identified with HLA tetramers, of five groups of patients based on their immunization histories. It will be further perform a phenotypic characterization of the tetramer+ anti-HLA B cells using spectral cytometry to study their nature and identify novel markers of memory subgroups.
Treatment groups
75 Participants
are divided into 5 treatment groupsGroup A: Sensitizing events : PregnancyActive comparator 1 intervention
Group B: Sensitizing events : Previous transplantation with thrombosisActive comparator 1 intervention
Group C: Sensitizing events : Previous transplantation with antobodyActive comparator 1 intervention
Group D: Whitout any sensitizing eventActive comparator 1 intervention
Group E: Sensitizing events : TransfusionActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Memory B cell heterogeneity
Memory B cell heterogeneity by single cell RNA sequencing
Time frame
At inclusionSecondary outcomes
1
Cytometry
Memory B cell heterogeneity by flow cytometry
Time frame
At inclusion (Day 0), second visit (up to18 months) , third visit (up to 24 months)Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: